Publications by authors named "Mehrshid Alai-Safar"
Pharmacol Res Perspect
February 2018
Article Synopsis
- The study was a randomized, double-blind trial aimed at comparing the pharmacokinetics, safety, and immunogenicity of the adalimumab biosimilar M923 with two reference products, US Humira and EU Humira, using a single 40-mg dose.
- Results showed that M923 demonstrated pharmacokinetic equivalence to both reference products, with geometric least squares means ratios for key endpoints (C_max, AUC_inf, AUC_336) falling within the acceptable range of 80%-125%.
- Adverse events were similar across all groups, mostly mild or moderate, and confirmed antidrug antibody response rates were also comparable, indicating that M923 is safe and tolerable like its
